U.S. stock futures rise on increased rate cut optimism; Dell’s outlook impresses
Mind Medicine (MindMed) Inc. NASDAQ:MNMD Chief Medical Officer Daniel Karlin, sold 7,704 common shares of the company on September 25, 2025, at a price of $9.77, for a total transaction value of $75,268. The stock, currently trading at $10.67, has shown remarkable momentum with a 66% return over the past year and is trading near its 52-week high of $11.02.
Following the transaction, Karlin directly owns 430,625 common shares of Mind Medicine (MindMed) Inc.
The sale was executed to cover withholding tax obligations related to the settlement of vested restricted stock units under a pre-arranged Rule 10b5-1 trading plan adopted on June 14, 2022.
The transaction was signed off by Mark Sullivan, Attorney-in-Fact for Dan Karlin
In other recent news, Mind Medicine Inc reported its second-quarter earnings for 2025, showcasing a robust cash position that is expected to sustain operations until 2027. The company’s earnings per share (EPS) were reported at -$0.50, which fell short of the projected -$0.37 by 35.14%. This earnings miss highlights ongoing challenges, although the company continues to focus on investment in research and development. Despite the earnings shortfall, the company’s future prospects seem to have maintained investor confidence, as reflected in the stock’s performance in aftermarket trading. Mind Medicine’s strategic focus remains on its long-term pipeline developments. No recent analyst upgrades or downgrades were reported, indicating a stable outlook among analysts. These developments underscore the company’s commitment to its strategic goals and financial planning.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.